Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in Switzerland.

ABSTRACT:

Introduction

In most patients with type 2 diabetes mellitus (T2DM) and progressive beta-cell insufficiency, insulin therapy is required to achieve sufficient glycemic control. However, insulin therapy may lead to weight gain and increasing risk of hypoglycemia. Glucagon-like peptide-1 receptor agonists are being used as add-on therapy to insulin with favorable metabolic effects. Nonetheless, to date only few studies exist reporting on the combination of liraglutide and insulin with a short follow-up period. The aim of this study was to evaluate the efficacy and safety of liraglutide as add-on to insulin in patients with T2DM over a time period of up to 24-28 months.

Methods

Data of patients with T2DM, treated with insulin and liraglutide at an outpatient clinic in a tertiary

SUBMITTER: Lipowsky C 

PROVIDER: S-EPMC4374072 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature